Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid

Haematologica. 2007 Jan;92(1):115-20. doi: 10.3324/haematol.10300.

Abstract

Class II major histocompatibility complex (MHC II) is normally silenced in plasma/multiple myeloma (MM) cells at the transcriptional level through downregulation of class II transactivator (CIITA), allowing MM cells to escape from immunological responses. Here we demonstrate that a retinoic acid receptor-alpha/beta-selective retinoid Am80 (tamibarotene) could induce the expression of functional MHC II molecules in human MM cell lines. Am80 upregulated expression of the interferon regulatory factor-1 gene, followed by enhancement of CIITA expression. This is the first report demonstrating that retinoid can induce the expression of MHC II in terminally-differentiated plasma/MM cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticarcinogenic Agents / pharmacology
  • Benzoates / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation
  • DNA, Complementary / metabolism
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic*
  • Genes, MHC Class II / genetics*
  • Histocompatibility Antigens Class II / biosynthesis*
  • Humans
  • Jurkat Cells
  • Multiple Myeloma / immunology*
  • Multiple Myeloma / metabolism
  • NF-kappa B / metabolism
  • Oligonucleotide Array Sequence Analysis
  • Retinoids / metabolism*
  • Tetrahydronaphthalenes / pharmacology*

Substances

  • Anticarcinogenic Agents
  • Benzoates
  • DNA, Complementary
  • Histocompatibility Antigens Class II
  • NF-kappa B
  • Retinoids
  • Tetrahydronaphthalenes
  • tamibarotene